MRK Welireg+Lenvima PDUFA: PFS Beat Over Cabozantinib

Merck (MRK) closed July 24 at $131.07, within $0.70 of its 52-week high of $131.74 and well above its January 2026 opening of $106.45. The stock has gained 23% year to date, driven by Keytruda’s continued dominance and pipeline progression. At a $323.7 billion market cap with $16.3 billion in Q1 revenue, Merck is the largest pure-play pharma company by market cap in the United States. Which raises the question: does a supplemental NDA for a combination therapy in renal cell carcinoma move this needle?

The FDA assigned a PDUFA date of October 4, 2026 for two supplemental NDAs seeking approval of WELIREG (belzutifan) plus LENVIMA (lenvatinib) for patients with advanced renal cell carcinoma whose disease progressed on or after anti-PD-1/PD-L1 therapy. That is 71 days from today. The data behind it comes from LITESPARK-011, a Phase 3 trial presented at the 2026 ASCO Genitourinary Cancers Symposium.

The Trial: LITESPARK-011

LITESPARK-011 randomized 747 patients 1:1 to belzutifan 120 mg plus lenvatinib 20 mg daily versus cabozantinib 60 mg daily. The dual primary endpoints were progression-free survival by blinded independent central review and overall survival. The key secondary endpoint was objective response rate. At the second interim analysis (IA2), with a median follow-up of 29.0 months, the results were:

• Median PFS: 14.8 months (95% CI 11.2-16.6) for belzutifan+lenvatinib versus 10.7 months (95% CI 9.2-11.1) for cabozantinib. Hazard ratio 0.70 (95% CI 0.59-0.84), p=0.00007. A 30% reduction in the risk of disease progression or death.
• ORR: 52.6% (95% CI 47.3-57.7) versus 40.2% (95% CI 35.2-45.3). Complete responses were 5.4% versus 1.1%, with 20 complete responses in the combination arm versus 4 in the cabozantinib arm.
• Median duration of response: 23.0 months (range 2.0-44.3+) versus 12.3 months (range 1.8+-35.9+). At 24 months, 49.5% of responses were ongoing in the combination arm versus 25.5% for cabozantinib.
• OS: 34.9 months (95% CI 27.5-NR) versus 27.6 months (95% CI 24.0-31.4). HR 0.85 (95% CI 0.68-1.05), p=0.06075. This did not cross the statistical significance boundary at interim analysis. Final OS analysis is pending.

The PFS benefit was consistent across subgroups, with one notable exception: patients with IMDC poor-risk disease showed no PFS advantage over cabozantinib. The benefit was driven by IMDC favorable-risk and intermediate-risk patients. That subgroup nuance matters for real-world uptake, because poor-risk RCC patients are the ones with the most unmet need.

On safety, the combination was not cleaner than cabozantinib. Grade 3 or higher treatment-emergent adverse events occurred in 84.1% of the combination arm versus 82.7% for cabozantinib. Anemia was substantially higher with belzutifan (69.2% any grade versus 25.6%), a known on-target effect of HIF-2alpha inhibition. Hypoxia occurred in 15.4% of combination patients versus 0% with cabozantinib. Cardiac dysfunction occurred in 7.0% versus 1.1%, with Grade 3 or higher cardiac dysfunction in 4.6% of combination patients. These are not negligible safety signals. The anemia and hypoxia are mechanistically tied to belzutifan’s HIF-2alpha inhibition, which means they cannot be designed away. They come with the mechanism.

What This Changes in RCC

The post-PD-1 RCC setting is crowded. The standard first-line regimen is now an IO-TKI combination, most commonly Opdivo (nivolumab) plus Cabometyx (cabozantinib) based on CheckMate-9ER, which showed a 23% reduction in the risk of death versus sunitinib and a median PFS of 15.4 months in IMDC intermediate/poor-risk patients. When patients progress on these first-line IO combinations, the treatment options narrow. Cabozantinib monotherapy has been the default second-line TKI, with median PFS of approximately 10-11 months in the post-IO setting based on trials like CONTACT-03.

LITESPARK-011 is the first Phase 3 trial to beat cabozantinib head-to-head in the post-IO setting. The 4.1-month PFS improvement (14.8 versus 10.7 months) and the near-doubling of median duration of response (23.0 versus 12.3 months) are clinically meaningful. If approved, belzutifan plus lenvatinib becomes the first oral dual-regimen to show superiority over a modern TKI in the post-checkpoint inhibitor setting.

But the OS trend (HR 0.85, p=0.06) is not yet statistically significant. The FDA may approve on PFS alone, which is common in oncology when the PFS benefit is this large (HR 0.70, p=0.00007) and the OS trend is directionally positive. But until the final OS analysis, the survival advantage remains suggestive rather than proven. That matters for uptake. Oncologists in the community setting may wait for mature OS data before switching from cabozantinib, especially given the higher anemia and cardiac dysfunction rates with the combination.

The Competitive Dynamics

Belzutifan is already approved as monotherapy in advanced RCC after PD-1/PD-L1 plus VEGF-TKI therapy, based on the LITESPARK-005 trial which showed a 24% reduction in the risk of progression or death versus everolimus. The combination with lenvatinib is a label expansion, not a new drug approval. Merck and Eisai are positioning this as a new standard of care in the post-IO setting, replacing single-agent cabozantinib.

The competitive threat comes from two directions. First, BMS is testing Opdivo plus Cabometyx in earlier lines and may push the IO-TKI combination into the post-IO refractory setting with modifications. Second, Exelixis, which markets cabozantinib, is running its own combination trials to defend Cabometyx’s position. The RCC treatment pathway is evolving rapidly, and a PFS advantage at one data cutoff does not guarantee durable market share if competitors produce their own positive combination data.

Lenvatinib is already approved in combination with Keytruda (MRK’s pembrolizumab) in endometrial cancer and as monotherapy in differentiated thyroid cancer, hepatocellular carcinoma, and in combination with everolimus in advanced RCC. Adding the belzutifan combination to the label extends Merck and Eisai’s dual-asset strategy in RCC. But both drugs are small molecules with generic competition looming. Lenvatinib’s composition of matter patent expires in 2027, though Eisai has pediatric exclusivity and formulation patents extending into the 2030s. Belzutifan’s patent runs through 2039. The combination label extends the commercial runway for both drugs, but lenvatinib’s eventual genericization limits the long-term upside.

Valuation: Does This Move Merck?

The honest answer is no, not materially. Merck’s $323.7 billion market cap is anchored by Keytruda, which generated $29.5 billion in 2025 revenue. WELIREG sales in 2025 were approximately $350 million. LENVIMA’s contribution to Merck’s revenue is reported under the Eisai partnership and is smaller. Even if the combination label doubles WELIREG’s revenue to $700 million annually over 3 years, that adds roughly 0.4% to Merck’s total revenue. The stock is not going to reprice on this approval.

Compare this to a mid-cap biotech where a similar label expansion could move the stock 15-30% on approval. Merck’s scale makes individual pipeline catalysts marginal to the equity story. The October 4 PDUFA matters for RCC patients and for Merck’s oncology narrative, but it does not move the stock needle. The 23% year-to-date gain in MRK is about Keytruda’s longevity, the subcutaneous Keytruda QLEX approval expected August 17, and the broader pipeline, not about a belzutifan label expansion.

For context on how size affects catalyst pricing, compare Merck to a company like Celcuity, where a single NDA acceptance can drive double-digit stock moves. Or look at the Summit ivonescimab PDUFA coin-flip analysis in the same oncology space, where a single asset drives the entire valuation. Merck processes the same regulatory events with near-zero stock impact because the base is so large.

Risks

1. OS non-significance. The FDA may approve on PFS, but if the final OS analysis (expected 2027) fails to confirm a survival benefit, the label could face restrictions or competitive pressure from regimens that do show OS improvement. The HR 0.85 at interim is close to the significance boundary; it could go either way.

2. Safety-driven dose modifications. The 84.1% Grade 3+ TEAE rate and the 4.6% Grade 3+ cardiac dysfunction rate may limit real-world adoption. Oncologists already managing post-IO patients with compromised health may be reluctant to add a regimen with this safety profile when single-agent cabozantinib is simpler to administer and monitor.

3. Competitive entrants. The RCC post-IO setting is the most active area in solid tumor oncology drug development. If a competitor produces Phase 3 OS data before Merck’s final OS readout, the belzutifan+lenvatinib label may be short-lived as standard of care.

4. Patent cliff dynamics. Keytruda’s IV formulation faces biosimilar entry in 2028. Merck’s entire strategic narrative is about bridging that cliff with subcutaneous Keytruda, pipeline assets, and business development. The belzutifan label expansion is a small piece of that bridge, not a load-bearing one.

The Verdict

The October 4 PDUFA for WELIREG plus LENVIMA is a high-probability approval. The PFS data is strong (HR 0.70, p=0.00007), the ORR is superior, and the duration of response is striking. The FDA has a strong precedent for approving oncology regimens on PFS benefits of this magnitude. I expect approval.

But for Merck investors, this is a non-event. A $700 million incremental revenue opportunity does not move a $324 billion stock. If you are holding MRK, you are holding it for Keytruda QLEX, the Ada-Esai partnership optionality, and the post-Keytruda pipeline strategy. The belzutifan label expansion is a marginal positive that adds a credible data point to Merck’s oncology breadth without changing the investment thesis.

For traders looking for a PDUFA catalyst play, Merck is the wrong vehicle. The stock’s 23% YTD run has already priced in pipeline optionality. A post-approval pop on October 4, if it happens, will be in the low single digits and likely fade within a week. The real RCC story to watch is whether the belzutifan+lenvatinib OS data matures to statistical significance, because that determines whether this label expansion is a 3-year bridge or a durable standard of care. That readout is 12 to 18 months away, not 71 days.

For our broader coverage of Merck’s pipeline and FDA catalysts, see the Q3 2026 FDA calendar and our analysis of the Pfizer Talzenna+Xtandi priority review in prostate cancer, which faces a similar question of whether a combination label expansion moves a mega-cap stock. Our guide to trading FDA catalysts covers why size matters when pricing regulatory events.